Posthuma EF - Search Results

1

HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.

Posthuma EF, Falkenburg JH, Apperley JF, Gratwohl A, Roosnek E, Hertenstein B, Schipper RF, Schreuder GM, D'Amaro J, Oudshoorn M, van Biezen JH, Hermans J, Willemze R, Niederwieser D. Posthuma EF, et al. Blood. 1999 Jun 1;93(11):3863-5. Blood. 1999. PMID: 10339494 Free article.

2

HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry.

Posthuma EF, Falkenburg JH, Apperley JF, Gratwohl A, Hertenstein B, Schipper RF, Oudshoorn M, Biezen JH, Hermans J, Willemze R, Roosnek E, Niederwieser D. Posthuma EF, et al. Leukemia. 2000 May;14(5):859-62. doi: 10.1038/sj.leu.2401774. Leukemia. 2000. PMID: 10803518

3

Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.

Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH. Posthuma EF, et al. Biol Blood Marrow Transplant. 2004 Mar;10(3):204-12. doi: 10.1016/j.bbmt.2003.11.003. Biol Blood Marrow Transplant. 2004. PMID: 14993886 Free article.

4

Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated.

Posthuma EF, van Bergen CA, Kester MG, de Paus RA, van Veelen PA, de Ru AH, Drijfhout JW, Lurvink EG, Willemze R, Falkenburg JH. Posthuma EF, et al. Haematologica. 2004 Sep;89(9):1062-71. Haematologica. 2004. PMID: 15377467

5

HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia.

Rutten CE, van Luxemburg-Heijs SA, Griffioen M, Marijt EW, Jedema I, Heemskerk MH, Posthuma EF, Willemze R, Falkenburg JH. Rutten CE, et al. Among authors: posthuma ef. Leukemia. 2008 Jul;22(7):1387-94. doi: 10.1038/leu.2008.90. Epub 2008 Apr 17. Leukemia. 2008. PMID: 18418406

6

High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.

Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP. Schrader AMR, et al. Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7. Blood. 2018. PMID: 29514783 Free article. No abstract available.

7

Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019.

van der Straten L, Levin MD, Dinnessen MAW, Visser O, Posthuma EFM, Doorduijn JK, Langerak AW, Kater AP, Dinmohamed AG. van der Straten L, et al. Blood Cancer J. 2023 Jan 13;13(1):15. doi: 10.1038/s41408-023-00784-z. Blood Cancer J. 2023. PMID: 36635262 Free PMC article.

8

Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in The Netherlands.

Dinmohamed AG, Posthuma EFM, Visser O, Kater AP, Raymakers RAP, Doorduijn JK. Dinmohamed AG, et al. Blood. 2018 Mar 22;131(12):1380-1383. doi: 10.1182/blood-2017-12-820381. Epub 2018 Jan 30. Blood. 2018. PMID: 29382643 Free article. No abstract available.

9

Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2018.

van der Straten L, Maas CCHM, Levin MD, Visser O, Posthuma EFM, Doorduijn JK, Langerak AW, Kater AP, Dinmohamed AG. van der Straten L, et al. Blood Cancer J. 2022 Apr 20;12(4):72. doi: 10.1038/s41408-022-00669-7. Blood Cancer J. 2022. PMID: 35444185 Free PMC article. No abstract available.

10

Decitabine in Older Patients with AML: Quality of Life Results of the EORTC-GIMEMA-GMDS-SG Randomized Phase III Trial.

Efficace F, Kicinski M, Coens C, Suciu S, van der Velden WJFM, Noppeney R, Chantepie SP, Griskevicius L, Neubauer A, Audisio E, Luppi M, Fuhrmann S, Foà R, Crysandt M, Gaidano G, Vrhovac R, Venditti A, Posthuma EFM, Candoni A, Baron F, Legrand O, Mengarelli A, Fazi P, Vignetti M, Giraut A, Wijermans PW, Huls GA, Lübbert M. Efficace F, et al. Among authors: posthuma efm. Blood. 2024 May 8:blood.2023023625. doi: 10.1182/blood.2023023625. Online ahead of print. Blood. 2024. PMID: 38717861

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

71 results

Search Page